1-2 of 2
Lakeisha Lubin, BS
Close
Sort by
Journal Articles

In Vitro , In Vivo , and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K-δ,γ Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed/Refractory T-Cell Lymphoma

Alison J. Moskowitz, MD, Raphael Koch, MD, Neha Mehta-Shah, MD, Patricia Myskowski, MD, Meenal Kheterpal, MD, Ahmet Dogan, MD PhD, Theresa Davey, MPAS, Natasha Galasso, BA, Marzouk Evan, BA, Monica Shah, BA, Nivetha Ganesan, BS, Lakeisha Lubin, BS, Youn H. Kim, MD, Michael Khodadoust, MD PhD, Timothy Almazan, MD, Julia Dai, MD, Eric D. Jacobsen, MD, David M. Weinstock, MD, Steven M. Horwitz, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 819.
https://doi.org/10.1182/blood.V130.Suppl_1.819.819
Published: 2017
Journal Articles

A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory B- and T-Cell Lymphomas

Neha Mehta-Shah, MD, Alison J. Moskowitz, MD, Matthew A. Lunning, DO, Peggy Lynch, Mark Scheuerman, Veenna Minnal, Natasha Galasso, BA, Anita Kumar, MD, John Gerecitano, MD PhD, Andrew D. Zelenetz, MD PhD, Paul A. Hamlin, MD, Ariela Noy, MD, Matthew J. Matasar, MD, Maria Lia Palomba, MD, Anas Younes, MD, Wendy Schaffer, MD, Ravinder Grewal, MD, Jurgen Rademaker, MD, Craig S. Sauter, MD, Parastoo B. Dahi, MD, Patricia Myskowski, MD, Meenal Kheterpal, MD, Ahmet Dogan, MD PhD, Melissa Pulitzer, MD, Lakeisha Lubin, BS, Laura Tang, Pharm. D, Nivetha Ganesan, BS, Ai Ni, PhD, Steven M. Horwitz, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 821.
https://doi.org/10.1182/blood.V130.Suppl_1.821.821
Published: 2017